Beta Bionics (BBNX) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Product innovation and differentiation

• Introduced a highly automated insulin delivery system, termed the Bionic Pancreas, featuring adaptive algorithms that minimize user and provider setup, enabling broader use by primary care providers.

• Clinical data shows equivalent outcomes when managed by primary care providers versus endocrinologists, supporting broader adoption.

• The system's outcomes are independent of user engagement, a first in diabetes technology, making it accessible to a wider patient base.

• Multi-form factor approach includes both tubed and tubeless options, aiming to serve diverse patient preferences and maximize population health impact.

• The new two-part durable-disposable design improves user experience and gross margins, with durable components lasting two years and disposables replaced every three days.

Market penetration and adoption

• Pump penetration in Type 1 diabetes remains around 40%, largely due to complexity for primary care providers; simplifying setup is key to growth.

• Clinical trials demonstrate that primary care providers can achieve outcomes on par with specialists, supporting expansion into primary care.

• Type 2 diabetes pump adoption is growing rapidly, with significant improvements in high A1C populations, despite no formal indication.

• A notable portion of users operate in fully closed-loop mode, requiring minimal interaction, and still achieve substantial A1C reductions.

Competitive landscape and business model

• Speed and agility in product development and integration, such as rapid CGM integration and over-the-air updates, are seen as core competitive advantages.

• Decision-making is streamlined, with an engineer-led culture and minimal bureaucracy, enabling fast execution and innovation.

• The company embraces a pay-as-you-go rental model, viewing it as beneficial for innovative products and patient choice, while noting potential challenges with competitive bidding and logistics.

• Pharmacy channel expansion is a strategic focus, with the company leading in moving durable pumps to this channel, though future adoption rates remain uncertain.